FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2093028623> ?p ?o ?g. }

• W2093028623 endingPage "431.e1" @default.
• W2093028623 startingPage "424" @default.
• W2093028623 abstract "Purpose To evaluate the effect of subconjunctival injection of bevacizumab on experimentally induced corneal neovascularization. Design Experimental animal study. Methods Twelve New Zealand white rabbits were involved, divided equally into four groups. Only one eye per rabbit was used. Topical instillation of 10 μl 5% NaOH solution was used, under general anesthesia, to induce corneal neovascularization secondary to corneal alkali burn in groups 2, 3, and 4. A single dose of 3.75 mg (25 mg/ml) bevacizumab was injected subconjunctivally. Group 1 (control group 1) was neither cauterized nor treated. Group 2 (control group 2) received a sham injection of balanced salt solution on day 14. Group 3 was treated on day 14 (after corneal neovascularization had been established). Group 4 was treated on day 1. Digital photographs were obtained and analyzed during the entire 28-day procedure. The area of neovascularization and scarring were measured in terms of the percentage of corneal surface affected. Results On day 28, the difference of neovascularization between groups 2, 3, and 4 was found to be statistically significant at the .05 level (one-way analysis of variance [ANOVA]): group 4 (4.7% ± 3.1%) < group 3 (13.3% ± 2.3%) < group 2 (41.0% ± 3.6%; P < .05, Mann–Whitney U test). In group 3, the area of neovascularization decreased 14 days after treatment by 42%. Neovascularization was almost completely absent in group 4. The development of scarring was unaffected by bevacizumab (P > .1, one-way ANOVA). No side effects were noted. Conclusions Subconjunctival administration of bevacizumab inhibits corneal neovascularization effectively in the rabbit experimental model, especially if administered early. To evaluate the effect of subconjunctival injection of bevacizumab on experimentally induced corneal neovascularization. Experimental animal study. Twelve New Zealand white rabbits were involved, divided equally into four groups. Only one eye per rabbit was used. Topical instillation of 10 μl 5% NaOH solution was used, under general anesthesia, to induce corneal neovascularization secondary to corneal alkali burn in groups 2, 3, and 4. A single dose of 3.75 mg (25 mg/ml) bevacizumab was injected subconjunctivally. Group 1 (control group 1) was neither cauterized nor treated. Group 2 (control group 2) received a sham injection of balanced salt solution on day 14. Group 3 was treated on day 14 (after corneal neovascularization had been established). Group 4 was treated on day 1. Digital photographs were obtained and analyzed during the entire 28-day procedure. The area of neovascularization and scarring were measured in terms of the percentage of corneal surface affected. On day 28, the difference of neovascularization between groups 2, 3, and 4 was found to be statistically significant at the .05 level (one-way analysis of variance [ANOVA]): group 4 (4.7% ± 3.1%) < group 3 (13.3% ± 2.3%) < group 2 (41.0% ± 3.6%; P < .05, Mann–Whitney U test). In group 3, the area of neovascularization decreased 14 days after treatment by 42%. Neovascularization was almost completely absent in group 4. The development of scarring was unaffected by bevacizumab (P > .1, one-way ANOVA). No side effects were noted. Subconjunctival administration of bevacizumab inhibits corneal neovascularization effectively in the rabbit experimental model, especially if administered early." @default.
• W2093028623 created "2016-06-24" @default.
• W2093028623 creator A5003651651 @default.
• W2093028623 creator A5011316933 @default.
• W2093028623 creator A5024275980 @default.
• W2093028623 creator A5058613033 @default.
• W2093028623 creator A5064573998 @default.
• W2093028623 creator A5074267070 @default.
• W2093028623 date "2008-03-01" @default.
• W2093028623 modified "2023-10-18" @default.
• W2093028623 title "Inhibition of Corneal Neovascularization by Subconjunctival Bevacizumab in an Animal Model" @default.
• W2093028623 cites W1560725142 @default.
• W2093028623 cites W176812056 @default.
• W2093028623 cites W1969144061 @default.
• W2093028623 cites W1970142574 @default.
• W2093028623 cites W1972599674 @default.
• W2093028623 cites W1985147506 @default.
• W2093028623 cites W1989176772 @default.
• W2093028623 cites W1993609386 @default.
• W2093028623 cites W2003926772 @default.
• W2093028623 cites W2010392784 @default.
• W2093028623 cites W2011842892 @default.
• W2093028623 cites W2017529362 @default.
• W2093028623 cites W2022952206 @default.
• W2093028623 cites W2022985798 @default.
• W2093028623 cites W2023523208 @default.
• W2093028623 cites W2033245558 @default.
• W2093028623 cites W2036983320 @default.
• W2093028623 cites W2042261909 @default.
• W2093028623 cites W2046507292 @default.
• W2093028623 cites W2061015788 @default.
• W2093028623 cites W2062305653 @default.
• W2093028623 cites W2077302818 @default.
• W2093028623 cites W2087780877 @default.
• W2093028623 cites W2100027888 @default.
• W2093028623 cites W2114159573 @default.
• W2093028623 cites W2142693543 @default.
• W2093028623 cites W4241938099 @default.
• W2093028623 doi "https://doi.org/10.1016/j.ajo.2007.11.003" @default.
• W2093028623 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/18207123" @default.
• W2093028623 hasPublicationYear "2008" @default.
• W2093028623 type Work @default.
• W2093028623 sameAs 2093028623 @default.
• W2093028623 citedByCount "109" @default.
• W2093028623 countsByYear W20930286232012 @default.
• W2093028623 countsByYear W20930286232013 @default.
• W2093028623 countsByYear W20930286232014 @default.
• W2093028623 countsByYear W20930286232015 @default.
• W2093028623 countsByYear W20930286232016 @default.
• W2093028623 countsByYear W20930286232017 @default.
• W2093028623 countsByYear W20930286232018 @default.
• W2093028623 countsByYear W20930286232019 @default.
• W2093028623 countsByYear W20930286232020 @default.
• W2093028623 countsByYear W20930286232021 @default.
• W2093028623 countsByYear W20930286232022 @default.
• W2093028623 countsByYear W20930286232023 @default.
• W2093028623 crossrefType "journal-article" @default.
• W2093028623 hasAuthorship W2093028623A5003651651 @default.
• W2093028623 hasAuthorship W2093028623A5011316933 @default.
• W2093028623 hasAuthorship W2093028623A5024275980 @default.
• W2093028623 hasAuthorship W2093028623A5058613033 @default.
• W2093028623 hasAuthorship W2093028623A5064573998 @default.
• W2093028623 hasAuthorship W2093028623A5074267070 @default.
• W2093028623 hasConcept C118487528 @default.
• W2093028623 hasConcept C126322002 @default.
• W2093028623 hasConcept C141071460 @default.
• W2093028623 hasConcept C178790620 @default.
• W2093028623 hasConcept C185592680 @default.
• W2093028623 hasConcept C2776694085 @default.
• W2093028623 hasConcept C2776882836 @default.
• W2093028623 hasConcept C2777802072 @default.
• W2093028623 hasConcept C2777844972 @default.
• W2093028623 hasConcept C2778271429 @default.
• W2093028623 hasConcept C2778996431 @default.
• W2093028623 hasConcept C2780394083 @default.
• W2093028623 hasConcept C2909954168 @default.
• W2093028623 hasConcept C3018023364 @default.
• W2093028623 hasConcept C31972630 @default.
• W2093028623 hasConcept C41008148 @default.
• W2093028623 hasConcept C71924100 @default.
• W2093028623 hasConcept C99476002 @default.
• W2093028623 hasConceptScore W2093028623C118487528 @default.
• W2093028623 hasConceptScore W2093028623C126322002 @default.
• W2093028623 hasConceptScore W2093028623C141071460 @default.
• W2093028623 hasConceptScore W2093028623C178790620 @default.
• W2093028623 hasConceptScore W2093028623C185592680 @default.
• W2093028623 hasConceptScore W2093028623C2776694085 @default.
• W2093028623 hasConceptScore W2093028623C2776882836 @default.
• W2093028623 hasConceptScore W2093028623C2777802072 @default.
• W2093028623 hasConceptScore W2093028623C2777844972 @default.
• W2093028623 hasConceptScore W2093028623C2778271429 @default.
• W2093028623 hasConceptScore W2093028623C2778996431 @default.
• W2093028623 hasConceptScore W2093028623C2780394083 @default.
• W2093028623 hasConceptScore W2093028623C2909954168 @default.
• W2093028623 hasConceptScore W2093028623C3018023364 @default.
• W2093028623 hasConceptScore W2093028623C31972630 @default.
• W2093028623 hasConceptScore W2093028623C41008148 @default.
• W2093028623 hasConceptScore W2093028623C71924100 @default.

• next